(VIANEWS) – Neurocrine Biosciences (NBIX), Genmab (GMAB), Hercules Technology Growth Capital (HTGC) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Neurocrine Biosciences (NBIX)
22.1% sales growth and 12.68% return on equity
Neurocrine Biosciences, Inc., a neuroscience-focused biopharmaceutical company, discovers, develops, and delivers various treatments for people with neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products also include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; NBI-827104 to treat rare pediatric epilepsy and other indications; and crinecerfont. The company's products in clinical development also comprise NBI-1065844 for the treatment of negative symptoms of schizophrenia; NBI-1065845 for the treatment of resistant depression; and NBI-1065846 for treating anhedonia in depression. It has license and collaboration agreements with Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL – Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; AbbVie Inc.; and Sentia Medical Sciences Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, Neurocrine Biosciences has a trailing twelve months EPS of $2.47.
PE Ratio
Neurocrine Biosciences has a trailing twelve months price to earnings ratio of 57.26. Meaning, the purchaser of the share is investing $57.26 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.68%.
Volume
Today’s last reported volume for Neurocrine Biosciences is 938631 which is 9.59% above its average volume of 856426.
Moving Average
Neurocrine Biosciences’s value is higher than its 50-day moving average of $136.86 and way above its 200-day moving average of $116.41.
Yearly Top and Bottom Value
Neurocrine Biosciences’s stock is valued at $141.43 at 06:22 EST, below its 52-week high of $148.37 and way above its 52-week low of $89.04.
Sales Growth
Neurocrine Biosciences’s sales growth is 25.7% for the present quarter and 22.1% for the next.
2. Genmab (GMAB)
17.9% sales growth and 14.78% return on equity
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
Earnings Per Share
As for profitability, Genmab has a trailing twelve months EPS of $0.96.
PE Ratio
Genmab has a trailing twelve months price to earnings ratio of 31.16. Meaning, the purchaser of the share is investing $31.16 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.78%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 8.9%, now sitting on 16.47B for the twelve trailing months.
3. Hercules Technology Growth Capital (HTGC)
12.1% sales growth and 21.07% return on equity
Hercules Capital, Inc. is a business development company. The firm specializing in providing venture debt, debt, senior secured loans, and growth capital to privately held venture capital-backed companies at all stages of development from startups, to expansion stage including select publicly listed companies and select special opportunity lower middle market companies that require additional capital to fund acquisitions, recapitalizations and refinancing and established-stage companies. The firm provides growth capital financing solutions for capital extension; management buy-out and corporate spin-out financing solutions; company, asset specific, or intellectual property acquisition financing; convertible, subordinated and/or mezzanine loans; domestic and international corporate expansion; vendor financing; revenue acceleration by sales and marketing development, and manufacturing expansion. It provides asset-based financing with a focus on cash flow; accounts receivable facilities; equipment loans or leases; equipment acquisition; facilities build-out and/or expansion; working capital revolving lines of credit; inventory. The firm also provides bridge financing to IPO or mergers and acquisitions or technology acquisition; dividend recapitalizations and other sources of investor liquidity; cash flow financing to protect against share price volatility; competitor acquisition; pre-IPO financing for extra cash on the balance sheet; public company financing to continue asset growth and production capacity; short-term bridge financing; and strategic and intellectual property acquisition financings. It also focuses on customized financing solutions, emerging growth, mid venture, and late venture financing. The firm invests primarily in structured debt with warrants and, to a lesser extent, in senior debt and equity investments. The firm generally seeks to invest in companies that have been operating for at least six to 12 months prior to the date of their investment. It prefers to invest in technology, energy technology, sustainable and renewable technology, and life sciences. Within technology the firm focuses on advanced specialty materials and chemicals; communication and networking, consumer and business products; consumer products and services, digital media and consumer internet; electronics and computer hardware; enterprise software and services; gaming; healthcare services; information services; business services; media, content and information; mobile; resource management; security software; semiconductors; semiconductors and hardware; and software sector. Within energy technology, it invests in agriculture; clean technology; energy and renewable technology, fuels and power technology; geothermal; smart grid and energy efficiency and monitoring technologies; solar; and wind. Within life sciences, the firm invests in biopharmaceuticals; biotechnology tools; diagnostics; drug discovery, development and delivery; medical devices and equipment; surgical devices; therapeutics; pharma services; and specialty pharmaceuticals. It also invests in educational services. The firm invests primarily in United States based companies and considers investment in the West Coast, Mid-Atlantic regions, Southeast and Midwest; particularly in the areas of software, biotech and information services. The firm prefers to invest between $10 million to $250 million in equity per transactions. It invests generally between $1 million to $40 million in companies focused primarily on business services, communications, electronics, hardware, and healthcare services. The firm invests primarily in private companies but also have investments in public companies. For equity investments, the firm seeks to represent a controlling interest in its portfolio companies which may exceed 25% of the voting securities of such companies. The firm seeks to invest a limited portion of its assets in equipment-based loans to early-stage prospective portfolio companies. These loans are generally for amounts up to $3 million but may be up to $15 million for certain energy technology venture investments. The firm allows certain debt investments have the right to convert a portion of the debt investment into equity. It also co-invests with other private equity firms. The firm seeks to exit its investments through initial public offering, a private sale of equity interest to a third party, a merger or an acquisition of the company or a purchase of the equity position by the company or one of its stockholders. The firm has structured debt with warrants which typically have maturities of between two and seven years with an average of three years; senior debt with an investment horizon of less than three years; equipment loans with an investment horizon ranging from three to four years; and equity related securities with an investment horizon ranging from three to seven years. The firm prefers to invest through its balance sheet capital. The firm formerly known as Hercules Technology Growth Capital, Inc. Hercules Capital, Inc. was founded in December 2003 and is based in Palo Alto, California with additional offices in Connecticut; Boston, Massachusetts; San Diego, California; Westport, Connecticut; Elmhurst, Illinois; Santa Monica, California; McLean, Virginia; New York, New York; Radnor, Pennsylvania; and Washington, District of Columbia and London, United Kingdom.
Earnings Per Share
As for profitability, Hercules Technology Growth Capital has a trailing twelve months EPS of $2.31.
PE Ratio
Hercules Technology Growth Capital has a trailing twelve months price to earnings ratio of 7.82. Meaning, the purchaser of the share is investing $7.82 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 21.07%.
Sales Growth
Hercules Technology Growth Capital’s sales growth is 15.7% for the ongoing quarter and 12.1% for the next.
Growth Estimates Quarters
The company’s growth estimates for the current quarter is 4.2% and a drop 3.8% for the next.
Moving Average
Hercules Technology Growth Capital’s value is higher than its 50-day moving average of $17.70 and way higher than its 200-day moving average of $16.35.
Revenue Growth
Year-on-year quarterly revenue growth grew by 22.4%, now sitting on 460.67M for the twelve trailing months.
4. MiMedx Group (MDXG)
9.5% sales growth and 62.09% return on equity
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, pressure ulcers, and burns; AmnioFix, a semi-permeable protective barrier membrane product for the treatment of wounds related to surgical procedures; EpiCord and AmnioCord that are dehydrated human umbilical cord allografts intended for homologous applications; and AmnioFill that consists of particles of connective tissue matrix derived from placental disc and placental membranes. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. is headquartered in Marietta, Georgia.
Earnings Per Share
As for profitability, MiMedx Group has a trailing twelve months EPS of $0.43.
PE Ratio
MiMedx Group has a trailing twelve months price to earnings ratio of 18.7. Meaning, the purchaser of the share is investing $18.7 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 62.09%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
MiMedx Group’s EBITDA is 3.57.
Volume
Today’s last reported volume for MiMedx Group is 576860 which is 21.21% below its average volume of 732200.
Moving Average
MiMedx Group’s value is below its 50-day moving average of $8.08 and above its 200-day moving average of $7.47.
Sales Growth
MiMedx Group’s sales growth is 23.7% for the present quarter and 9.5% for the next.
5. International General Insurance Holdings Ltd. (IGIC)
8% sales growth and 24.36% return on equity
International General Insurance Holdings Ltd. provides specialty insurance and reinsurance solutions worldwide. The company operates through three segments: Specialty Long-tail, Specialty Short-tail, and Reinsurance segments. It offers a portfolio of specialty lines insurance products and services for energy, property, construction and engineering, ports and terminals, general aviation, political violence, casualty, financial institutions, marine liability, and treaty reinsurance. The company was founded in 2001 and is based in Amman, Jordan.
Earnings Per Share
As for profitability, International General Insurance Holdings Ltd. has a trailing twelve months EPS of $2.17.
PE Ratio
International General Insurance Holdings Ltd. has a trailing twelve months price to earnings ratio of 6.24. Meaning, the purchaser of the share is investing $6.24 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 24.36%.
6. Franklin Resources (BEN)
7.9% sales growth and 8.43% return on equity
Franklin Resources, Inc. is a publicly owned asset management holding company. Through its subsidiaries, the firm provides its services to individuals, institutions, pension plans, trusts, and partnerships. It launches equity, fixed income, balanced, and multi-asset mutual funds through its subsidiaries. The firm invests in the public equity, fixed income, and alternative markets. Franklin Resources, Inc. was founded in 1947 and is based in San Mateo, California with an additional office in Hyderabad, India.
Earnings Per Share
As for profitability, Franklin Resources has a trailing twelve months EPS of $1.9.
PE Ratio
Franklin Resources has a trailing twelve months price to earnings ratio of 14.16. Meaning, the purchaser of the share is investing $14.16 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.43%.
Volume
Today’s last reported volume for Franklin Resources is 10772100 which is 221.76% above its average volume of 3347790.
Revenue Growth
Year-on-year quarterly revenue growth grew by 1.2%, now sitting on 7.87B for the twelve trailing months.
7. Pro-Dex (PDEX)
6.2% sales growth and 10.68% return on equity
Pro-Dex, Inc. designs, develops, and manufactures powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company was founded in 1978 and is headquartered in Irvine, California.
Earnings Per Share
As for profitability, Pro-Dex has a trailing twelve months EPS of $0.84.
PE Ratio
Pro-Dex has a trailing twelve months price to earnings ratio of 20.41. Meaning, the purchaser of the share is investing $20.41 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.68%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 11.6%, now sitting on 48.24M for the twelve trailing months.
Sales Growth
Pro-Dex’s sales growth for the next quarter is 6.2%.
8. Kamada Ltd. (KMDA)
5.1% sales growth and 3.94% return on equity
Kamada Ltd., together with its subsidiaries, provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. It has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. Kamada Ltd. was incorporated in 1990 and is headquartered in Rehovot, Israel.
Earnings Per Share
As for profitability, Kamada Ltd. has a trailing twelve months EPS of $0.15.
PE Ratio
Kamada Ltd. has a trailing twelve months price to earnings ratio of 38.2. Meaning, the purchaser of the share is investing $38.2 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.94%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Kamada Ltd.’s EBITDA is 2.01.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 250% and 50%, respectively.
Yearly Top and Bottom Value
Kamada Ltd.’s stock is valued at $5.73 at 06:22 EST, way under its 52-week high of $6.53 and way higher than its 52-week low of $4.08.
